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The epigenome of differentiated somatic cells can be
reprogrammed to a pluripotent state by nuclear transfer into
enucleated oocytes or by fusion with pluripotent cells such
as embryonic stem cells (ESCs) [1]. More recently, it has
been shown that overexpression of defined transcription
factors via transduction of viral vectors can reprogram
mouse and human somatic cells to induced pluripotent stem
cells (iPSCs) [2-4]. This new approach greatly simplifies the
generation of pluripotent cells, bypassing many technical
and ethical hurdles, and brings closer the possibility of using
patient-specific cells in cell-based therapy. However, the use
of viruses to deliver the reprogramming factors entails
permanent genetic alterations that render the cells
inappropriate for many in vitro and  in vivo applications.
Several approaches have recently been devised to generate
iPSCs free of the exogenous reprogramming factor genes,
including the use of non-integrating approaches for
transgene delivery [5,6]. Four papers published this year
describe a variety of novel approaches. Soldner et al. [7]
have used the Cre/loxP recombination system to produce
human iPSCs free of exogenous reprogramming genes.
Woltjen et al. [8] and Kaji et al. [9] demonstrate that the
piggyBac (PB) transposon system can be used both to
introduce reprogramming genes and induce pluripotency
and then to remove the transgenes from established iPSC
lines. Finally, Yu et al. [10] describe the successful use of
another type of non-integrating vector to obtain iPSCs free
of vector and transgenes.
T To ow wa ar rd ds s   r re ep pr ro og gr ra am mm mi in ng g   w wi it th ho ou ut t   a a   t tr ra ac ce e
ESCs are derived from the inner cell mass of mammalian
embryos, and are characterized by their capacity to self-
renew indefinitely in culture and their potential to
differentiate into all cell types of the body. During
development, cells become more restricted in their ability to
generate other cell types and somatic cells do not normally
revert to an earlier, more primitive developmental stage.
Nonetheless, the developmental memory of a somatic cell
can be erased, and the cell can be induced to revert to a
pluripotent stage by forced expression of a combination of
transcription factors that usually includes Oct4, Sox2, Klf4
and c-Myc [2,3]. The same approach has been used to
reprogram human adult fibroblasts and keratinocytes into
iPSCs [3,11]. Reprogramming adult human cells from
patients with complex diseases such as Parkinson’s disease
and Alzheimer’s disease holds great promise of providing
invaluable disease models, as well as platforms for drug
screening. Along the road, iPSC-derived specialized cells
could also serve in transplantation therapy.
As a proof of concept, disease-specific iPSCs have been
generated [12-14], and have been used to model disease [14]
as well as to ease the symptoms of sickle-cell anemia in
animal models after gene correction and proper differen-
tiation [15]. However, current methods for generating iPSCs
are unsuitable for therapeutic applications. Most methods
rely on the use of retroviruses or lentiviruses to permanentlyintegrate the reprogramming factor genes into the genome
of the target cell. Although the reprogramming factors are
often silenced after complete reprogramming, the iPSCs
maintain significant residual transgene expression and could
display transgene reactivation. This could have an impact on
their differentiation into specialized cells and, more
importantly, increase the risks of tumorigenesis [16]. The
added risk of insertional mutagenesis highlights the need for
the development of safer non-integrating vehicles to deliver
the reprogramming factors.
Early attempts to generate iPSCs without viral integration
included the repeated transient transfection of plasmid-
based vectors into mouse embryonic fibroblasts [5], and the
use of adenoviruses in mouse liver cells [6]. However, in
both cases, the reprogramming efficiency was extremely low
and the kinetics was too slow, and no iPSCs have been
generated from human cells using such methods. Soldner et
al. [7] have now successfully exploited the Cre/loxP-recom-
bination system to efficiently reprogram fibroblasts into
iPSCs from five patients with idiopathic Parkinson’s disease
using excisable lentiviruses. Transgenes were removed by
transfecting the iPSCs with Cre-recombinase and applying
selection to remove untransfected cells or isolating trans-
fected cells by cell sorting. Out of 180 clones isolated, 16 had
lost the integrated transgenes (approximately 9% excision
efficiency), and maintained a pluripotent state for more than
15 passages.
When these iPSCs were induced to differentiate under
neuronal differentiation protocols, dopaminergic neurons
were derived regardless of the age of the donor, thus
highlighting the feasibility of using iPSC-derived cells in
transplantation therapy for Parkinson’s disease in the future
[7]. Interestingly, Soldner et al. found, by genome-wide
gene-expression analysis, that the factor-free iPSCs are more
similar to human ESCs than they are to the parental iPSCs
carrying the transgenes. These observations suggest that
residual transgene expression could have an effect on the
molecular characteristics of reprogrammed cells. The
complete removal of vector and transgene sequences from
established iPSCs is therefore essential if iPSCs and ESCs are
to be accurately compared.
An alternative method for removing the reprogramming
factors from iPSCs relies on the PB transposition system, in
which a transiently expressed transposase catalyzes the
excision of transgenes flanked by inverted terminal repeats
[8,9]. The PB system is effective in mouse and human cells,
and performs efficient and precise excision without leaving a
footprint behind [17,18]. Woltjen et al. [8] generated iPSCs
by transfecting mouse embryonic fibroblasts with a plasmid
expressing the PB transposase and a vector containing Oct4,
Sox2, Klf4, and c-Myc open reading frames linked with 2A
peptide sequences and flanked by the required inverted
terminal repeats. The polycistronic sequence served to
reduce the required number of excisions. The efficiency and
kinetics of iPSC generation using this method were similar to
those observed using other viral vector approaches. Out of
48 iPSC lines established, two contained only a single copy
of the polycistronic sequence, indicating that the reprogram-
ming factors are sufficient in single copy for reprogramming.
The transient expression of PB transposase in the two single-
copy cell lines and subsequent subcloning resulted in the
removal of the linked reprogramming factor DNA at an
efficiency greater than 2%; within these subclones, the
majority examined (10 out of 11) had reverted to the wild-
type sequence. The factor-free iPSCs were fully reprogrammed
as determined by their contribution to chimera development
and tetraploid embryo complementation. Woltjen et al. [8]
were also successful in generating iPSCs from human
embryonic fibroblasts using the PB transposon system,
although no removal of transgene sequences was shown. In an
accompanying paper, Kaji et al. [9] combined a Cre/loxP-based
method with a non-viral 2A system and found that expres-
sion of the exogenous transgenes could no longer be detected
in stably reprogrammed iPSCs derived from mouse embryonic
fibroblasts, suggesting that they had been eliminated.
The removal of reprogramming transgenes using Cre/loxP-
recombination or the PB transposition system provides a
practical approach for the generation of factor-free human
iPSCs, but requires additional tedious steps that might
hinder widespread applications of iPSCs for various applica-
tions. In addition, in the case of the recombinase-based
approach, residual vector sequences are left behind,
increasing the risk of insertional mutagenesis. Yu et al. [10]
have made an effort to simplify the derivation of transgene-
free human iPSCs by exploiting an oriP/EBNA1 (Epstein-
Barr nuclear antigen-1)-based episomal vector. Plasmids
containing oriP maintain stable extrachromosomal replica-
tion in 1% of transfected cells when the viral protein EBNA1
is provided, being lostat a rate of 3 to 5% per cell generation
after removal of selection [19]. Yu et al. [10] transfected
human fibroblasts once with a combination of episomal
vectors expressing two to three reprogramming factors from
IRES2-linked open reading frames.
Initial attempts to generate iPSCs by delivering IRES2-linked
open reading frames for the human reprogramming factors
OCT4, SOX2, KLF4, c-MYC, NANOG and LIN28 via multiple
oriP/EBNA1 vectors failed as a result of substantial cell death,
possibly due to the high level of c-MYC expression. However,
when the SV40 large T (SV40LT) gene was included in the
mixture to counteract the possible side effects of c-MYC, the
authors managed to derive iPSCs from human foreskin
fibroblasts in two independent experiments [10]. PCR analysis
of iPSC clones revealed persistence of the episomal vectors
over a prolonged period of time, perhaps a requirement for
successful reprogramming, but no integration in the genome
was observed. Subcloning of iPSC lines (at passage 9 and 10)
to select for spontaneous loss of episomes led to the isolation
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subclones derived). The iPSC subclones were fully
reprogrammed and had normal karyotypes.
This approach is promising as there is no integration of
transgenes into the genome, and the exogenous DNA can be
removed by gradual loss of the episomes during extended
culture without drug selection, and without the need for
further genetic manipulation. However, the protocol as it
stands now requires the delivery into somatic cells of a large
number of genes (six reprogramming factors in addition to
SV40LT and EBNA1) in multiple vectors (two to three), with
low reprogramming efficiency (around 0.001%). In addition,
the fact that episomal loss is spontaneous and not directed
will require subcloing of iPSC lines and prolonged culture.
Improved efficiency and a simpler approach are therefore
needed for this method to be more widely applied.
I Im mp pr ro ov ve em me en nt t   s st ti il ll l   n ne ee ed de ed d
The first iPSCs derived from murine somatic cells were
reported three years ago, followed by similar studies in
human cells a year later. Despite great advances, much still
needs to be clarified before iPSCs can be fully utilized in
basic research and clinical applications. Reprogramming of
somatic cells by forced expression of defined factors is
clearly different from reprogramming through somatic cell
nuclear transfer or fusion with pluripotent cells. The
efficiency and kinetics of reprogramming are not the same,
with reprogramming by defined factors being a random
process that requires many progressive nonspecific epi-
genetic remodeling events to occur over a prolonged period
of time (usually 2 weeks for mouse cells, and 3-4 weeks for
human cells).
Whether reprogramming by defined factors can be further
optimized will depend on a better understanding of the
mechanisms involved, and improvements in the methods for
generating transgene-free iPSCs such as those discussed
here [7-10]. It might be possible to combine multiple
approaches to achieve this, such as combining episomal
vectors for gene delivery and small molecules to improve
reprogramming efficiency and shorten the time required.
The latter will be essential, as prolonged protocols and
extended culture times and subcloning might introduce
genetic or epigenetic abnormalities that would render the
iPSCs unsuitable for clinical application. What will be even
more desirable is to avoid genetic material and manipulation
altogether. Indeed, the number of reprogramming factors
required to generate iPSCs has been reduced [20,21], and
neural stem cells have recently been reprogrammed by the
forced expression of Oct4 only [22]. In the future, it may be
possible by treatment with small molecules, direct intro-
duction of proteins, or a combination of both to generate
iPSCs without any genetic manipulation.
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